Autres langues Valerio Therapeutics Deutsche Boerse AG

Actions

C4X

FR0010095596

Produits pharmaceutiques

Marché Fermé - Deutsche Boerse AG Autres places de cotation 08:01:37 14/07/2026			Varia. 5j.	Varia. 1 janv.
0,3850 ^EUR	-11,49 %		+10,00 %	+171,13 %

17/06	Bourse : Renault et Thales dans les drones, BMW dans le dur, SpaceX vers l'infini
17/06	Powell ne viendra plus aux soirées

Autres langues

01/07	Valerio Therapeutics Announces Binding Offer for the Proposed Acquisition of Etherna Immunotherapies, Creating a Global Leader in Targeted RNA Medicines
01/07	Valerio Therapeutics : announces binding offer for the proposed acquisition of Etherna Immunotherapies, creating a global leader in targeted RNA medicines
01/07	Valerio Therapeutics Société anonyme signed a letter of intent to acquire eTheRNA immunotherapies NV for an enterprise value of ?30 million.
17/06	Valerio Therapeutics Names New CEO
16/06	Valerio Therapeutics Appoints Gilles Besin as Chief Executive Officer and Announces Results of its Annual General Meeting
16/06	Valerio Therapeutics Société Anonyme Announces Board and Executive Changes
16/06	Valerio Therapeutics Société Anonyme Announces CEO Changes
16/06	Valerio Therapeutics : Appoints Gilles Besin as Chief Executive Officer and Announces Results of its Annual General Meeting
19/05	Valerio Therapeutics Signs Binding Term-sheet for V-Body Platform Collaboration
18/05	Valerio Therapeutics enters into collaboration & exclusive license with seed-stage biotech co
18/05	Valerio Therapeutics Announces Binding Term-Sheet for Collaboration and Exclusive License With Seed-Stage Biotech Company
18/05	Valerio Therapeutics Enters Binding Term-Sheet for Collaboration and Exclusive License with Stealth-Mode Biotech Company
18/05	Valerio Therapeutics : announces binding term-sheet for collaboration and exclusive license with seed-stage biotech company
04/05	Valerio Therapeutics : Inside Information / Other news releases
04/05	Valerio Therapeutics Announces Launch of Invimmune and Provides Update on in Vivo Cell Therapy Approaches
04/05	Valerio Therapeutics Launches New Company for In Vivo Cell Therapies
04/05	Valerio Therapeutics Announces the Launch of InVimmune, a New Company Dedicated to Developing Differentiated in Vivo Cell Therapy Approaches
29/04	Valerio Therapeutics : Annual financial and audit reports / Terms of availability of the annual financial report
29/04	Valerio Therapeutics Publishes Its 2025 Annual Results and Annual Financial Report, and Confirms the Strategic Transformation of Its Operating Model
28/04	Valerio Therapeutics : publishes its 2025 annual results and annual financial report, and confirms the strategic transformation of its operating model
28/04	Valerio Therapeutics Société anonyme Reports Earnings Results for the Full Year Ended December 31, 2025
17/12	Valerio Therapeutics Announces the Appointment of Professor Eric Vivier as Observer to Its Board of Directors
15/12	Valerio Therapeutics : announces the appointment of Eric Vivier as observer to its Board of Directors
12/12	Valerio Therapeutics : annonce la désignation Du Professeur Eric Vivier en qualité d’Observateur de son Conseil d’Administration
12/12	Valerio Therapeutics : COMPLETION OF THE MERGER BETWEEN VALERIO THERAPEUTICS AND ITS SUBSIDIARY VALOUR BIO